No new responders to Epizyme's Phase I leukemia therapy

Epizyme Inc. (NASDAQ:EPZM) lost $2.90 (11%) to $23.70 on Thursday after publication of an abstract showing that no new patients added to a Phase I trial of EPZ-5676 to treat acute leukemia achieved complete responses. The abstract was published in advance of the American Society of Hematology (ASH) meeting in December.

Epizyme reported in January that two of the first 16 evaluable adults achieved CRs in the study in patients with advanced hematologic malignancies, including acute leukemia with rearrangements of the myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX) gene. As of July 31, 28 patients were evaluable for efficacy. ...